Drug intelligence / Profile preview

coagulation factor IX (Erasmus MC)

Development stage
Phase 4
Lead developer
Erasmus MC
Modality
Recombinant Proteins and Enzymes
Administration
Intravenous
01

Overview

Factor IX concentrates are a class of biologic replacement therapies used to treat and prevent bleeding episodes in patients with hemophilia B, a genetic disorder caused by a deficiency of functional coagulation factor IX. These concentrates include plasma-derived formulations (pdFIX), recombinant versions (rFIX), and extended half-life variants (EHL-FIX). By restoring levels of factor IX in the intrinsic coagulation pathway, these therapies enable the formation of thrombin and subsequent blood clots. Clinical research, such as the OPTI-CLOT TARGET study sponsored by Erasmus University Medical Center, focuses on optimizing prophylactic dosing through pharmacokinetic (PK)-guided strategies to tailor treatment to individual patient needs and activity levels.

Other names
factor IX concentratesFIX concentratesplasma-derived factor IXrecombinant factor IXpdFIXrFIXEHL-FIX
02

Targets

FCGRT (Neonatal crystallizable fragment receptor)COL4 (Collagen IV)F9 (Coagulation Factor IX)

Beyond the preview

Go deeper on coagulation factor IX (Erasmus MC).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on coagulation factor IX (Erasmus MC).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call